Sea2Sky Advisory
A biopharma consulting company
Leverage deep, hands-on R&D experience and connectivity to address your critical drug development challenges.
Company
In- and out-licensing strategies
Pitch deck development
R&D organizational builds.
Portfolio
Indication and disease area assessments
Internal portfolio prioritization
Assets
Development options and decision matrices (Go / No Go)
Risk assessments
Integrated, IND to PoC development planning
What makes Sea2Sky Advisory different?
Drug development is a set of complex risk-based trade-offs.
Leveraging deep drug development experience across multiple therapeutic areas and across all major modalities we will work with you to understand your drivers and customize our recommendations accordingly.
⇓
The Sea2Sky Advisory approach builds from a foundation of asset MoA, preclinical datasets and patient level data, up through aggregate datasets and analytics.
⇓
Our Development Guidance and Advice is Practical and Hands-on. There is no template for your challenges and there won’t be a template for the solutions.
Expert drug development guidance and advice to complement your existing R&D team
Innovative End to End drug development advice and strategies
Planning and then managing through critical R&D investment decisions and asset inflection points
Indications
Hematology (malignant / non-malignant)
Oncology / Immuno-Oncology
Cardiovascular
Fibrosis
Ex / in vivo CAR
Protein degradation
Small / large molecules
Platforms
About Sea2Sky Advisory principal Jonathan Leith, PhD
Deep, hands on drug development experience:
Most recently accountable for >30 IND-to-PoC assets across hematology, oncology, in / ex vivo cell therapy; prior experience in gene therapy, cardiovascular and virology.
Drove >10 INDs, 5 PoCs, 5 pivotal designs, 2 NME approvals, multiple indication expansions and HTA approvals.
Key R&D partner to business development on multiple assessments and acquisitions
C suite connectivity with biopharma, biotech and venture capital
Trusted to provide unvarnished truths with practical and thoughtful R&D perspectives.
Builder of high performing R&D organizations:
Developed and implanted translational trouble-shooting team (Clinical Mechanisms)
Advised on complex R&D restructurings and org challenges.
